Houston mobile vet company plans to roll out services statewide

pet care delivered

A Houston vet has seen growth in business for her mobile vet company due to the pandemic. Now, she's planning major growth. Photo courtesy of Rollin' Vets

It's safe to say that the real winners of work-from-home trends that sparked due to the pandemic are our pets. Dogs and cats that were used to not seeing their owners for eight hours every work day now have 24-hour access to attention, treats, and ear scratches.

This increased attention pets are getting from their owners has also meant an increased awareness of pet health, says Katie Eick, founder of Houston-based Rollin' Vets, a startup that has mobilized veterinary services.

"People are home and observing their animals more. They're seeing and recognizing things they might not have if they were at work all day," Eick says.

Each of the four mobile units can do most everything a brick-and-mortar clinic can. Photo courtesy of Rollin' Vets

That's, of course, not the only way the pandemic has affected business for Eick. She founded her company in 2016 and was seeing steady growth as delivery and on-demand services like Uber, DoorDash, etc. increased in use and awareness.

"We were continuously growing slowly — then COVID hit. It really cemented that … all the convenience services are in the forefront of people's minds." Eick tells InnovationMap. "COVID made it clear that this was a necessary service."

Like a lot of businesses, vet clinics closed to the public and only accept drop-off patients. This new way of seeing pets coupled with the fact that most people are working remotely from home also played to the advantage Rollin' Vets — why drive your pet to drop off at a clinic when the vet can come to your driveway?

COVID-19 closures and social distancing practices also called for a rise in veterinary telemedicine — something that Eick says has been challenging for her to utilize both due to the board of medicine having strict regulations in place as well as the challenges trying to provide virtual animal care poses.

Katie Eick always wanted to be able to offer mobile services. Photo courtesy of Rollin' Vets

"Humans can get on and tell you their symptoms, where they hurt, and how they are feeling. Animals can't do that," Eick says.

Earlier in the pandemic, she did provide some telemedicine visits. The board, which bans telemedicine care for pets not previously seen by a vet or pets that haven't been seen in over a year, loosened the regulations to allow for virtual care of pets if the vet has ever seen the animal. This was helpful for providing refill medications, for instance.

Then, Eick had an appointment with a four-year-old French bulldog that changed her mindset on telemedicine. The dog had some stomach issues when his owner made an appointment with Eick. By the time she got to the dog, he had more or less seemed fine — he was eating again and didn't seem despondent in any way. But when Eick performed his exam, she found a mass.

"If I would have just looked at that dog over a video chat, he would have died," Eick says, adding that she got the dog right into surgery at a nearby facility.

In this case, telemedicine wouldn't have provided a solution for the animal, but Eick hasn't ruled virtual care out in general.

"I do think there's place for it, but we have to be really careful," she says.

At this point, Eick has more than proven her value proposition for her company. She has four mobile units with a team of four vets, six technicians, and four receptionists. As far as funding goes, she's pitched to the Houston Angel Network and is looking for angel investors. She's also planning on looking into crowdfunding as an option.

She's planning for growth — starting with Dallas and San Antonio — and sees the company adopting a franchise model that will eventually take Rollin' Vets out of state.

"We're aiming to be a nationwide brand," Eick says.

Rollin' Vets is planning to fundraise on NextSeed next month. Photo courtesy of Rollin' Vets

Dr. Colleen O'Connor has adapted immunotherapy treatments to be used in dogs. Courtesy of CAVU Biotherapies

Houston-based veterinary biotech startup modernizes cancer treatments for dogs

Paw-dern medicine

More than three years after its founding, Houston-based veterinary biotech company CAVU Biotherapies recently accomplished a significant milestone. In October, CAVU's specialized immunotherapy was administered to its first cancer patient: a black Labrador in Pennsylvania diagnosed with B-cell lymphoma.

Dr. Colleen O'Connor, CEO and founder of CAVU Biotherapies, established the company in July 2015 with a goal to help pets live longer post-cancer diagnoses. O'Connor, who earned a PhD in toxicology with a specialty in immunology, has more than a decade of hands-on experience researching cancer treatments.

"Our goal is to scale up and be able to increase our dogs' qualities of life with us," O'Connor said. "We want to keep families intact longer and we want to be able to modernize cancer care for our animals."

At CAVU, O'Connor dedicates her time to modernizing cancer care for dogs by developing an Autologous Prescription Product, otherwise known as adoptive T-cell therapy for dogs. The T-cell therapy is currently offered as a companion treatment to other canine cancer treatments, such as chemotherapy, radiation or surgery, O'Connor said.

Historically, cancer research for animals has lagged behind that of humans, and cancer diagnoses have come late due to the language barrier, O'Connor said. Of the dogs who enter remission, a majority of them relapse within 10 months to one year, she said.

"A majority [of dogs] are diagnosed at stage four, and you have to become very aggressive," O'Connor said. "For B-cell lymphoma, with the current treatments right now and the current standard of [therapies], less than 20 percent make it to two years post-diagnosis."

Launching CAVU
O'Connor first began studying T-cell therapy for humans with cancer during her post-doctoral fellowship at M.D. Anderson Cancer Center. Her fellowship also partnered with Texas A&M University's Small Animal Hospital to develop a clinical trial studying the effects of adoptive T-cell therapies on dogs with B-cell lymphoma.

T-cell therapy is a cellular-based treatment in which a type of white blood cells — or the cells that fight off tumors and infections — are harvested from blood samples drawn from patients. The cells are then injected back into the patient through an IV to fight the cancerous cells, O'Connor said.

Unexpectedly, O'Connor's 19-year-old dog, Bubbles, was diagnosed with transitional cell carcinoma in 2008 and later dying from it in December 2009. Five years later, O'Connor's sister's 6-year-old dog, Daisy, also died from transitional cell carcinoma. O'Connor said she remembers feeling helpless as she watched the dogs succumb to the disease.

"I was giving them drugs and protocols that were from 1980 … and I was really upset that there wasn't much more we could do for our dogs — especially because I treat my dogs like family," O'Connor said.

That was when O'Connor realized she wanted to help prevent other people from feeling the pain of losing their furry family members. While T-cell therapy is not a new method of treating cancer in humans, O'Connor focused on modifying the serum to create a treatment plan appropriate for dogs.

However, launching a company focusing specifically on treating cancer in animals was not without its challenges; O'Connor said she had to learn how to start a business, make industry connections, and adopt an entrepreneurial mindset.

To help with this, CAVU also connected with various entrepreneurial accelerators, such as Houston Technology Center and Station Houston, which are associations that help place young businesses in front of investors.

CAVU later became a member of the Houston Angel Network — a group of private investors of high net worth individuals that as a group invest in startups. By presenting her business to HAN and its investors, CAVU was able to gain financial backing.

CAVU also recently joined the Capital Factory in early 2018, an Austin-based accelerator program for entrepreneurs in Texas. O'Connor said the program has helped her meet investors, mentors and other startups.

"The way I overcame a lot of this [the early challenges] is by education, listening and trying to navigate and talk with as many of the right people as I could that had experience," she said.

The future of CAVU
Since CAVU treated its first patient in October, CAVU's adoptive T-cell therapy treatment has been administered to six dogs, O'Connor said. CAVU's T-cell therapy is currently available at more than 12 veterinary clinics across the country, including clinics in Texas, Florida, Pennsylvania, New York, North Carolina, and Missouri.

Additionally, four Houston-area clinics currently offer the T-cell therapy treatment: Garden Oaks Veterinary Clinic, Bayou City Veterinary Hospital, Memorial-610 Hospital for Animals, and Sugar Land Veterinary Specialists.

In order for a dog to be considered as a candidate — though it is ultimately up to the veterinarian on whether the T-cell therapy is right for specific dogs — the dogs must weigh more than 8 pounds, not be allergic to mouse or cow products and have no active autoimmune diseases.

The company also launched a new clinical trial with A&M University in October, looking at the effects of CAVU's T-cell therapy coupled with reduced chemotherapy periods for dogs, from roughly 19 to 26 weeks of chemotherapy to 6 to 8 weeks.

While CAVU's therapy is currently only available for dogs, O'Connor said her team plans to modify the T-cell therapy to be administered in other animals.

"We have a lot of cat owners ask us [about treatment] and we are going to do that for the next round in funding," she said. "We're going to look at how to translate this for cats and eventually horses."

O'Connor said that CAVU will launch more clinical trials with A&M University's Small Animal Hospital in the future, with CAVU aiming to make T-cell therapy treatments for cats and horses available in 2020.

Looking back, O'Connor said she has come a long way in her career path: from working with sea animals at the Newport Aquarium in Kentucky to studying human immunology and toxicology, but she's returned to studying animals.

"It's amazing how I pivoted, but at the end of the day I kind of came back to animals … and I came back full circle in a way I could have never expected," she said.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston biosciences company opens new sequencing center for drug development

bioscience breakthroughs

Houston-based Avance Biosciences has launched the Next-Generation Sequencing Center of Excellence, designed to enhance the company’s sequencing capabilities for drug development. Specifically, the facility at the company’s main campus in Northwest Houston will pursue breakthroughs in biologics, cell therapy and gene therapy.

In the drug industry, sequencing refers to studying nucleotides in DNA and RNA molecules. Nucleotides are the building blocks of DNA and RNA.

“This is a major milestone for Avance Biosciences as we continue to support the evolving needs of biologics and cell and gene therapy developers,” Xuening “James” Huang, co-founder, CEO and chief technology officer of Avance, said in a news release. “By consolidating state-of-the-art sequencing platforms and scientific talent, we’ve created a highly capable organization ready to solve complex genomic challenges with precision and compliance.”

In 2013, Avance rolled out next-generation sequencing (NGS) that complies with federal guidelines. Since then, Avance “has remained at the forefront of regulated sequencing services,” the company said. “The launch of the (new center) strengthens the company’s ability to deliver accurate, reproducible, and regulatory-aligned sequencing data across a wide array of therapeutic modalities.”

Cal Froberg, senior vice president of sales and marketing at Avance, said pharmaceutical and biotech clients trust the company’s technical capabilities and regulatory compliance.

“With the ever-changing global landscape and increasing scrutiny around international sample shipments, conducting advanced, cost-effective NGS testing domestically is now more feasible than ever,” Froberg said. “Our clients have confidence that their samples will remain in the U.S.”

Avance, founded in 2010, plans to hold an open house at the new facility in September to showcase its capabilities, technology, talent, and services. The company’s services include sequencing, molecular biology, cell-based testing, and bioanalytical testing.

Texas cybersecurity co. expands unique train-to-hire model to Houston

job search

It’s increasingly more difficult to ensure the confidentiality, integrity, and availability of proprietary data and information in the ever-changing, ever-evolving digital world.

Cyberattacks, including malware, phishing, and ransomware, are becoming increasingly common and sophisticated, posing a consistent threat to a company’s sustainability and bottom line.

To combat that trend, Nukudo, a San Antonio-based cybersecurity workforce development company, is expanding its initiative to bridge the global cybersecurity talent gap through immersive training and job placement to Houston.

“We saw that there was a need in the market because there's a shortage of skilled manpower within the cybersecurity industry and other digital domains,” says Dean Gefen, CEO of NukuDo. “So, our initial goal was to take a large pool of people and then make them to be fully operational in cybersecurity in the shortest amount of time.”

The company refers to the plan as the “training-to-employment model,” which focuses on providing structured training to select individuals who then acquire the skills and knowledge necessary to secure and maintain fruitful careers.

The company identifies potential associates through its proprietary aptitude test, which recognizes individuals who possess the innate technical acumen and potential for success in various cybersecurity roles, regardless of their level of education.

“We take in people from all walks of life, meaning the program is purely based on the associate’s potential,” Gefen says. “We have people who were previously aircraft engineers, teachers, graphic designers, lawyers, insurance agents and so forth.”

Once selected, associates are trained by cybersecurity experts while gaining hands-on experience through scenario-based learning, enabling them to be deployed immediately as fully operational cybersecurity professionals.

The program training lasts just six months—all paid—followed by three years of guaranteed employment with NukuDo.

While in training, associates are paid $ 4,000 per month; then, they’re compensated by nearly double that amount over the next three years, ultimately pushing their salaries to well into the six figures after completing the entire commitment.

In addition to fostering a diverse talent pipeline in the cybersecurity field, NukuDo is creating a comprehensive solution to address the growing shortage of technical talent in the global workforce.

And arming people with new marketable skills has a litany of benefits, both professional and personal, Gefen says.

“Sometimes, we have associates who go on to make five times their previous salary,” says Gefen. “Add to that fact that we had someone that had a very difficult life beforehand and we were able to put him on a different path. That really hits home for us that we are making a difference.

Nulkudo currently has partnerships with companies such as Accenture Singapore and Singapore Airlines. Gefen says he and his team plans to have a new class of associates begin training every month by next year and take the model to the Texas Triangle (Houston, Austin and Dallas)—then possibly nationwide.

“The great thing about our program is that we train people above the level of possible threat of replacement by artificial intelligence,” Gefen says. “But what we are also doing, and this is due to requirements that we have received from clients that are already hiring our cyber professionals, is that we are now starting to deliver AI engineers and data scientists in other domains.”

“That means that we have added more programs to our cybersecurity program. So, we're also training people in data science and machine learning,” he continues.

All interested candidates for the program should be aware that a college degree is not required. NukuDo is genuinely interested in talented individuals, regardless of their background.

“The minimum that we are asking for is high school graduates,” Gefen says. “They don't need to have a college degree; they just need to have aptitude. And, of course, they need to be hungry to make this change.”

2 Houston universities declared among world’s best in 2026 rankings

Declaring the Best

Two Houston universities are in a class of their own, earning top spots on a new global ranking of the world's best universities.

Rice University and University of Houston are among the top 1,200 schools included in the QS World University Rankings 2026. Ten more schools across Texas make the list.

QS (Quacquarelli Symonds), a London-based provider of higher education data and analytics, compiles the prestigious list each year; the 2026 edition includes more than 1,500 universities from around the world. Factors used to rank the schools include academic reputation; employer reputation; faculty-student ratio; faculty research; and international research, students, and faculty.

In Texas, University of Texas at Austin lands at No. 1 in the state, No. 20 in the U.S., and No. 68 globally.

Houston's Rice University is close behind as Texas' No. 2 school. It ranks 29th in the U.S. and No. 119 in the world. Unlike UT, which fell two spots globally this year (from No. 66 to 68), Rice climbed up the charts, moving from 141st last year to No. 119.

University of Houston impresses as Texas' 4th highest-ranked school. It lands at No. 80 in the U.S. and No. 556 globally, also climbing about 100 spots up the chart.

Rice and UH are on a roll in regional, national, and international rankings this year.

Rice earned top-15 national rankings by both Niche.com and Forbes last fall. Rice claimed No. 1 and UH ranked No. 8 in Texas in U.S. News & World Report's 2025 rankings. Rice also topped WalletHub's 2025 list of the best colleges and universities in Texas for 2025.

More recently, in April, both UH and Rice made U.S. News' 2025 list of top grad schools.

In all, 192 U.S. universities made the 2026 QS World University Rankings — the most of any country. Topping the global list is the Massachusetts Institute of Technology (MIT).

“The results show that while U.S. higher education remains the global leader, its dominance is increasingly challenged by fast-rising emerging systems,” says the QS World University Rankings report. “A decade ago, 32 American universities [were] featured in the world’s top 100; today, that number has dropped to 26, and only 11 of these institutions have improved their position this year."

The 12 Texas universities that appear in the QS World University Rankings 2026 list are:

  • University of Texas at Austin, No. 20 in the U.S. and No. 68 in the world (down from No. 66 last year).
  • Rice University, No. 29 in the U.S. and No. 119 in the world (up from No. 141 last year).
  • Texas A&M University, No. 32 in the U.S. and No. 144 in the world (up from No. 154 last year).
  • University of Houston, No. 80 in the U.S. and No. 556 in the world (up from 651-660 last year).
  • University of Texas at Dallas, No. 85 in the U.S. and No. 597 in the world (down from 596 last year).
  • Texas Tech University, No. 104 in the U.S. and No. 731-740 in the world (unchanged from last year).
  • University of North Texas, No. 123 in the U.S. and No. 901-950 in the world (up from 1,001-1,200 last year)
  • Baylor University, tied for No. 136 in the U.S. and at No. 1,001-1,200 in the world (unchanged from last year).
  • Southern Methodist University, tied for No. 136 in the U.S. and at 1,001-1,200 in the world (unchanged from last year).
  • University of Texas Arlington, tied for No. 136 in the U.S. and at 1,001-1,200 in the world (unchanged from last year).
  • University of Texas at San Antonio, tied for No. 136 in the U.S. and at 1,001-1,200 in the world (unchanged from last year).
  • University of Texas at El Paso, No. 172 in the U.S. and at 1,201-1,400 in the world (down from 1,001-1,200 last year).
---

This article originally appeared on CultureMap.com.

View All Listings